Mapping the natural history of Huntington disease

被引：1
作者：
Barker, Roger A. [1 ]
Mason, Sarah L. [1 ]
机构：
[1] Univ Cambridge, John van Geest Ctr Brain Repair, Dept Clin Neurosci, Cambridge CB2 0PY, England
来源：
NATURE REVIEWS NEUROLOGY | 2014年 / 10卷 / 01期
关键词：
D O I：
10.1038/nrneurol.2013.253
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
A key challenge to improving the design of clinical trials in Huntington disease (HD) has been the limited data on the natural history of HD. A recent prospective longitudinal study has provided important information in this regard, which could be useful for future translation of disease-modifying therapies for early-stage HD.
引用
收藏
页码：12 / 13
页数：3
相关论文
共 6 条
[1]  
Burgunder J-M, 2011, PLOS CURR, V3
[2]  
Dorsey E. R., JAMA NEUROL, DOI DOI 10.1001/JAMANEUR0L.2013.4408
[3]  
Huntington Study Group COHORT Investigators & Dorsey E, 2012, PLOS ONE, V7
[4]   Emerging drug therapies in Huntington's disease [J].
Mason, Sarah L. ;
Barker, Roger A. .
EXPERT OPINION ON EMERGING DRUGS, 2009, 14 (02) :273-297
[5]   Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data [J].
Tabrizi, Sarah J. ;
Scahill, Rachael I. ;
Owen, Gail ;
Durr, Alexandra ;
Leavitt, Blair R. ;
Roos, Raymund A. ;
Borowsky, Beth ;
Landwehrmeyer, Bernhard ;
Frost, Chris ;
Johnson, Hans ;
Craufurd, David ;
Reilmann, Ralf ;
Stout, Julie C. ;
Langbehn, Douglas R. .
LANCET NEUROLOGY, 2013, 12 (07) :637-649
[6]   Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis [J].
Tabrizi, Sarah J. ;
Scahill, Rachael I. ;
Durr, Alexandra ;
Roos, Raymund A. C. ;
Leavitt, Blair R. ;
Jones, Rebecca ;
Landwehrmeyer, G. Bernhard ;
Fox, Nick C. ;
Johnson, Hans ;
Hicks, Stephen L. ;
Kennard, Christopher ;
Craufurd, David ;
Frost, Chris ;
Langbehn, Douglas R. ;
Reilmann, Ralf ;
Stout, Julie C. .
LANCET NEUROLOGY, 2011, 10 (01) :31-42
1